Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

A trial that aims to find the best treatment for people with advanced prostate cancer

What is this study about?

Prostate cancer accounts for around one fifth of all cancers among men. In the UK there are around 25,000 new cases of prostate cancer each year, and around 10,000 deaths.

Most men are given hormone therapy if their prostate cancer has spread (metastasised), or if the cancer is very likely to spread. This usually stops the tumour from growing for a while. But in most cases over time the tumour will start to grow again.

The aim of this trial is to try to prevent the tumour re-growth by adding other treatment(s) to the hormone therapy. The trial is currently using enzalutamide and abiraterone in combination with hormone therapy or, for newly diagnosed metastatic patients only, radiotherapy in combination with hormone therapy. Celecoxib, zoledronic acid, docetaxel and abiraterone alone have previously been tested.

Results so far

STAMPEDE "M1 Radiotherapy Comparison" Results: Summary:


STAMPEDE "M1 Radiotherapy Comparison" Results:


STAMPEDE results on docetaxel and zoledronic acid: summary for health workers


The STAMPEDE prostate cancer trial: docetaxel and zoledronic acid results for patients


STAMPEDE abiraterone results: summary


STAMPEDE abiraterone results

Type of study

Randomised trial

Contact details

Who is funding the study?

The trial is mainly funded by the charity Cancer Research UK with extra support from four pharmaceutical companies: Pfizer, Sanofi-Aventis, Novartis, Janssen, Astellas and Clovis.

When is it taking place?

Recruitment will end 31st March 2023, with no further arms being added to the study.

Where is it taking place?

Follow up continues at participating hospitals in the UK. The participating Swiss sites are now closed and are no longer involved in the follow up or recruitment of participants.

Who is included?

Men with newly diagnosed advanced prostate cancer, or with relapsing prostate cancer.